Plain-English translation of NCT04865250 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing atezolizumab—a type of immunotherapy drug—combined with two chemotherapy drugs (carboplatin and nab-paclitaxel) given before surgery in patients with early-stage lung cancer. The goal is to shrink tumors as much as possible before your surgeon removes them. Researchers want to understand whether this combination works better than standard treatment alone.
Immunotherapy has shown promise in treating advanced lung cancer, and doctors want to learn whether using it earlier—before surgery—might help patients with early-stage disease live longer and have better outcomes. This medication is being paired with standard chemotherapy to see if the combination is more effective than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
You will receive three cycles of treatment (each cycle is 3 weeks) before your scheduled surgery. During each cycle, you'll come to the hospital for intravenous infusions of the medication and chemotherapy drugs on specific days. After completing all three cycles, you will undergo standard lung cancer surgery with lymph node removal. Throughout the trial, you'll have blood tests, imaging scans, and tissue biopsies to monitor how well the treatment is working and to help researchers understand which patients respond best.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Germany